Prognostic Value of PD-L1 in Patients with Hepatocellular Carcinoma

被引:6
作者
Pei, Renguang [1 ]
Zhang, Weixuan [2 ]
Wang, Sufen [2 ]
Huang, Xi [2 ]
Zou, Yinghua [1 ]
机构
[1] Peking Univ, Hosp 1, Dept Intervent Radiol & Vasc Surg, Beijing 100034, Peoples R China
[2] Wannan Med Coll, Yijishan Hosp, Dept Pathol, Wuhu, Peoples R China
关键词
hepatocellular carcinoma; PD-L1; survival; prognosis; LIGAND; 1; EXPRESSION; POSTOPERATIVE RECURRENCE; CELL; DEATH;
D O I
10.7754/Clin.Lab.2018.180839
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The aim of the study is to investigate whether programmed death ligand l (PD-L1) on tumor cells has prognostic significance in patients with hepatocellular carcinoma. Methods: A cohort of 143 patients with hepatocellular carcinoma was enrolled. PD-L1 expression was detected by immunohistochemistry. The association of PD-L1 expression with clinical characteristics and survival was analyzed. Results: PD-L1 positive rate in our study was 13.3% (19/143). None of clinical characteristics, including gender, age, virus infection, AFP, vascular invasion, tumor size, and number, was significantly associated with PD-L1 expression (p > 0.05). PD-L1 expression was significantly associated with cirrhosis (p = 0.016). PD-L1 expression was not significantly associated with survival (Log-rank p = 0.076; HR: 0.363 p = 0.091). Conclusions: PD-L1 expression failed to have a markedly significant prognostic association with survival in patients with hepatocellular carcinoma.
引用
收藏
页码:693 / 698
页数:6
相关论文
共 20 条
[1]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[2]   Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma: Relationship With Clinical and Pathological Features [J].
Calderaro, Julien ;
Rousseau, Benoit ;
Amaddeo, Giuliana ;
Mercey, Marion ;
Charpy, Cecile ;
Costentin, Charlotte ;
Luciani, Alain ;
Zafrani, Elie-Serge ;
Laurent, Alexis ;
Azoulay, Daniel ;
Lafdil, Fouad ;
Pawlotsky, Jean-Michel .
HEPATOLOGY, 2016, 64 (06) :2038-2046
[3]   PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma [J].
Chen, Chang-Long ;
Pan, Qiu-Zhong ;
Zhao, Jing-Jing ;
Wang, Ying ;
Li, Yong-Qiang ;
Wang, Qi-Jing ;
Pan, Ke ;
Weng, De-Sheng ;
Jiang, Shan-Shan ;
Tang, Yan ;
Zhang, Xiao-Fei ;
Zhang, Hong-Xia ;
Zhou, Zi-Qi ;
Zeng, Yi-Xin ;
Xia, Jian-Chuan .
ONCOIMMUNOLOGY, 2016, 5 (07)
[4]   PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation [J].
Cree, Ian A. ;
Booton, Richard ;
Cane, Paul ;
Gosney, John ;
Ibrahim, Merdol ;
Kerr, Keith ;
Lal, Rohit ;
Lewanski, Conrad ;
Navani, Neal ;
Nicholson, Andrew G. ;
Nicolson, Marianne ;
Summers, Yvonne .
HISTOPATHOLOGY, 2016, 69 (02) :177-186
[5]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502
[6]   Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Dikshit, Rajesh ;
Eser, Sultan ;
Mathers, Colin ;
Rebelo, Marise ;
Parkin, Donald Maxwell ;
Forman, David ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386
[7]   Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma [J].
Gao, Qiang ;
Wang, Xiao-Ying ;
Qiu, Shuang-Jian ;
Yamato, Ichiro ;
Sho, Masayuki ;
Nakajima, Yoshiyuki ;
Zhou, Jian ;
Li, Bai-Zhou ;
Shi, Ying-Hong ;
Xiao, Yong-Sheng ;
Xu, Yang ;
Fan, Jia .
CLINICAL CANCER RESEARCH, 2009, 15 (03) :971-979
[8]   Immune Checkpoint Blockade in Hepatocellular Carcinoma: Current Progress and Future Directions [J].
Hato, Tai ;
Goyal, Lipika ;
Greten, Tim F. ;
Duda, Dan G. ;
Zhu, Andrew X. .
HEPATOLOGY, 2014, 60 (05) :1776-1782
[9]   Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma [J].
Huang, Chun-yu ;
Wang, Ying ;
Luo, Guang-yu ;
Han, Feng ;
Li, Yong-qiang ;
Zhou, Zhong-guo ;
Xu, Guo-liang .
JOURNAL OF IMMUNOTHERAPY, 2017, 40 (09) :323-333
[10]  
Kan G, 2015, EUR REV MED PHARMACO, V19, P3063